Table 2.
Studies investigating the implications of COVID-19 in CVD patients.
| Patient sample size | Age | Underlying CVD | CVD complications | Molecular markers studied | Mortality | Reference |
|---|---|---|---|---|---|---|
| N = 187 | 58.50 (mean age) | 66 (35.3%)- CVD, 52 (27.8%) – myocardial injury |
CHD, cardiomyopathy, myocardial injury, frequent malignant arrhythmias | TnT, NT-proBNP | 69.44% (25 of 36) | [121] |
| N = 416 | 64 (median age) | Cardiac injury (19.7%) | CHD (10.6%), cerebrovascular disease (5.3%) | hs-TnІ, CK-MB, NT-proBNP, MYO | 51.2% (42 of 82) | [122] |
| N = 191 | 56 (median age) | HT (30%), CHD (8%) | HF, arrhythmia, MI | D-dimer, serum ferritin, IL-6, LDH, hs-cTnІ, SOFA |
n/a | [123] |
| N = 273 | 58 (mean age) | n/a | Heart injury | CK-MB, MYO, Ultra Tn I, NT-proBNP | 10.5% | [124] |
| N = 1 | 64 (F) | Atrial fibrillation, HT | HF, cardiogenic shock, tachyarrhythmias | Hs-TnT, IL-6, ferritin | n/a | [125] |
| N = 38,906 | 59 (median age) | CVD (17%) HT (50%) |
n/a | n/a | 37% (CVD) 66% (HT) |
[66] |
CVD=Cardiovascular disease, HT = hypertension, CHD = coronary heart disease, NT-proBNP = N-terminalpro-B-type natriuretic peptide, CK-MB = creatinine kinase myocardial band, IL-6 = interleukin 6, LDH = lactate dehydrogenase, hs-cTnI = high-sensitivity cardiac troponin І, HF = heart failure, MI = myocardial infarction, MYO = myohemoglobin, Ultra Tn I = cardiac troponin I, SOFA = sequential organ failure assessment, hs-TnІ = high sensitivity troponinin І, n/a = not applicable.